2018 ANZUP GU Preceptorship

The 2018 ANZUP GU Preceptorship (Kidney, Bladder, Testicular)

Date: 30 November - 1 December 2018
Location: Novotel Melbourne Glen Waverley
Convenor: Eva Segelov
Preceptors: Ian Davis, Craig Gedye, George Hruby, Jarad Martin, Declan Murphy, Shomik Sengupta, Ben Tran
Read bios

Applications are now open for the 2018 ANZUP GU Preceptorship (Kidney, Bladder, Testicular). Places are limited and expected to fill quickly and applications will close Friday 28 September 2018.

The Preceptorship is an interactive learning model for the education of medical oncology trainees and junior consultants in the evidence-based management of genitourinary (GU) malignancies. The specific objective for participants is to develop an understanding of the evolution of GU cancer treatment through review of landmark clinical trials, with mentorship by experts in the field.

The 1½ day course will cover landmark clinical trials in kidney, bladder and testicular cancers. Target participants are trainees and junior consultants (first 5 years of practice) in medical, radiation and surgical oncology. Areas to be covered are multimodality management of early, locally advanced and metastatic disease and supportive care.

To apply you must state why you would like to do the course, which papers you would like to present, and have a case study ready to present. The first fully completed applications will be the first to be confirmed.

To apply please click here.

More information about the 2018 ANZUP GU Preceptorship can be found here.

Successful applicants will be supported (with travel and accommodation) to attend this exciting initiative. Registration for all attendees is $250.

If you are not already a member of ANZUP, please submit a free membership application here (note membership is a condition of attendance).

We look forward to your participation at this interactive learning experience.


About the 2018 Convenor

Professor Eva Segelov

Discipline: Medical Oncology

Eva Segelov is Professor and Director of Oncology at Monash University and Monash Health, Melbourne. She has specialist interest in the diagnosis and management of upper and lower gastrointestinal cancers, including neuroendocrine tumours. Prof Segelov has led multiple national and international oncology clinical trials and has published over 100 articles, expert reviews and book chapters. She is a frequent invited speaker at national and international conferences and has convened the COSA and AGITG Annual Scientific Meetings. In 2015 she co-founded the international research collaborative the Commonwealth Neuroendocrine Tumour Society (CommNETS). In 2016 she was nominated as a European Society of Medical Oncology (ESMO) Faculty member for the CUP, Endocrine Tumours and Others group; in 2018 she was appointed as ESMO Faculty member for Gastrointestinal Cancer. Professor Segelov is Associate Editor for the ASCO publication of Journal of Global Oncology (ASCO) and the online video journal JoVE. Professor Segelov heads a translational cancer laboratory at Monash University. Having been awarded the Vice Chancellors medal for teaching excellence at UNSW and following attendance at the Harvard-Macy short course for Medical Education, Eva developed the unique “Seminal Advances Preceptorship” educational model, that has run now over more than 5 years, in multiple tumour streams.

About the 2018 Preceptors

Professor Ian Davis

Discipline: Medical Oncology

Professor Ian Davis MB BS PhD FRACP FAChPM is a medical oncologist, cancer immunologist and clinician-scientist. He is Professor of Medicine, Monash University and Eastern Health, and Head of the Eastern Health Clinical School (EHCS), where he is responsible for all clinical research within Eastern Health through the Monash Eastern Clinical Research Unit (ECRU). He holds honorary appointments with the Olivia Newton-John Cancer Research Institute (formerly Ludwig Institute for Cancer Research) and Austin Health, and is an adjunct Associate Professor of the University of Melbourne, and Associate of the University of Sydney. His primary clinical interests are in urologic cancer and in melanoma, and his primary research interests are in cancer immunology and the biology of urologic cancers. He heads the Uro-oncology Laboratory at EHCS in which basic and translational research occurs in prostate cancer, and leads the Eastern Health genitourinary cancer clinical trial program. He is the founder of the Urologic Oncology Group of the Clinical Oncology Society of Australia (COSA), member of COSA Council, and previously COSA Board director. He is founder of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd (ANZUP), and chair of the ANZUP Board and of its Scientific Advisory Committee.

Dr Craig Gedye

Discipline: Medical Oncology

Craig Gedye is a physician/scientist, dual trained as a medical oncologist and basic science researcher. He works for patients with melanoma, brain, kidney, prostate, testis, and bladder cancer at the Calvary Mater Newcastle, and is the Clinical Research Director at the NSW Statewide Biobank. Craig chairs the Renal Cancer Subcommittee for the ANZUP Cancer Trials Group, and undertakes translational and basic cancer research at the Hunter Medical Research Institute, University of Newcastle.

His research focus is on cancer heterogeneity; why treatments work for some patients but not others. This challenging problem spans the research spectrum from patient experience to basic science.

Associate Professor George Hruby

Discipline: Radiation Oncology

A/Prof George Hruby completed a fellowship at the Royal Prince Alfred Hospital in 1999 and was awarded a clinical fellowship at the University of Toronto. He spent 13 months in Toronto at a high volume academic centre focused on genito-urinary cancers. In December 2000 he commenced as Staff Specialist in Radiation Oncology at the Royal Prince Alfred Hospital, (now Lifehouse). Clinical milestones have included the establishment of the High Dose Rate brachytherapy program at Royal Prince Alfred Hospital with over 300 implants performed since inception in 2002. Whilst at RPA, George was instrumental in leading the introduction of more sophisticated techniques for the treatment of prostate cancer such as image guided radiation treatment (IGRT) in 2007, IMRT (intensity modulated radiation treatment) for anal cancer in 2009, and for prostate cancer in 2010. In 2014 the first prostate cancer patients were treated with SABR (stereotactic ablative body radiotherapy) for oligo-metastatic disease.

He has mentored and taught radiation oncology registrars as well as medical students, presented at many scientific meetings and co-authored over 75 peer reviewed publications. He currently works at Royal North Shore Hospital where he has established a stereotactic focal prostate re-treatment protocol for those with intra-prostatic recurrence following definitive RT. Other areas of interest include the adoption of PSMA-PET into the GU radiation treatment field.

Conjoint Professor Jarad Martin

Discipline: Radiation Oncology

Jarad Martin is a Radiation Oncologist and departmental Director of Research working at the Calvary Mater Newcastle. He completed his fellowship in 2005 and undertook a genitourinary oncology clinical research fellowship at the Princess Margaret Hospital in Toronto winning the academic excellence in research award from that institution. His primary clinical and research interests are in urologic and gastrointestinal cancers, including the application of stereotactic radiotherapy for genitourinary tumours. In 2006 he accepted a position in Regional Queensland in Toowoomba and established the Toowoomba Cancer Research Centre (TCRC). Jarad assumed the Australasian Primary Investigator role for the successful PROFIT clinical trial randomizing men with prostate cancer to receive either a standard 8 week course or an experimental 4 weeks regimen of radiotherapy. He relocated to Newcastle in 2012 and continued to develop a number of senior roles in national bodies. He was the Clinical Liaison for TROG from 2012-15 and was the chair of the Faculty of Radiation Oncology Research Committee from 2011-15. He has been on the executive of the Faculty of Radiation Oncology Genitourinary Group (FROGG) as well as the scientific advisory committee of ANZUP. Jarad has several currently accruing multicentre prospective clinical trials, > 70 peer reviewed publications, and has also recently completed a mid-career PhD.

Mr Paul Anderson

Discipline: Urology

Paul Anderson is a Consultant Urologist at the Royal Melbourne Hospital and Epworth Hospital.

He has an active research portfolio involving surgical, medial and biomarker trials particularly in the field of bladder cancer. He is a reviewer for a number of journals, sits on the Melbourne Health Ethics Committee for Research and is an examiner for the Urology Fellowship Examinations.

Professor Shomik Sengupta

Discipline: Urology

Shomik Sengupta is a consultant urologist and Director of Research & Training at Austin Health, and Clinical Associate Professor at the Department of Surgery (Austin) of Melbourne University. Shomik has a practice with a uro-oncology subspecialty interest – including open, laparoscopic and robotic cancer surgery. He is currently the chair of the Victorian training committee and leader of the GU Oncology advisory group within USANZ. Shomik also has a strong interest in urologic research, including involvement in clinical trials through the ANZUP trials group. He has completed a Masters in Surgery (2002) and a Doctorate in Medicine (2014) through the University of Melbourne and has more than 70 original publications to date.

Dr Ben Tran

Discipline: Medical Oncology

Ben Tran is a consultant Medical Oncologist based at Peter MacCallum Cancer Centre. He also holds a Clinician Scientist appointment at the Walter and Eliza Hall Institute. Clinically, his focus lies entirely within the genitourinary (GU) tumour stream, in particular, testicular and urothelial cancers. Following his medical oncology training in Australia, Ben completed an overseas Fellowship in Drug Development and Urological cancers at Princess Margaret Cancer Centre in Toronto, Canada. There he gained extensive experience in treating GU cancers, conducting Phase I clinical trials, implementing a large scale molecular profiling program and managing large multi-centre databases containing real world patient data. These experiences have allowed him to establish a burgeoning career in Australia, in GU cancers, Early Drug Development and RWD. Ben currently leads the GU clinical trials program at Peter MacCallum Cancer Centre and is Chair of the GU Tumour Group within Cancer Trials Australia, and Chair of the ANZUP Germ Cell Subcommittee.

We thank and acknowledge the 2018 Preceptorship sponsors



© ANZUP 2020. All rights reserved.